Gilead Sciences, Inc. $GILD Shares Sold by Patton Albertson Miller Group LLC

Patton Albertson Miller Group LLC lowered its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 55.2% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 3,344 shares of the biopharmaceutical company’s stock after selling 4,116 shares during the period. Patton Albertson Miller Group LLC’s holdings in Gilead Sciences were worth $410,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Ares Financial Consulting LLC acquired a new position in Gilead Sciences during the fourth quarter worth about $28,000. Corundum Trust Company INC acquired a new position in Gilead Sciences during the third quarter worth about $26,000. Financial Consulate Inc. raised its position in Gilead Sciences by 85.8% during the fourth quarter. Financial Consulate Inc. now owns 236 shares of the biopharmaceutical company’s stock worth $29,000 after acquiring an additional 109 shares during the last quarter. North Star Investment Management Corp. raised its position in Gilead Sciences by 54.8% during the fourth quarter. North Star Investment Management Corp. now owns 243 shares of the biopharmaceutical company’s stock worth $30,000 after acquiring an additional 86 shares during the last quarter. Finally, BOCHK Asset Management Ltd purchased a new stake in shares of Gilead Sciences during the fourth quarter worth about $31,000. Institutional investors and hedge funds own 83.67% of the company’s stock.

Gilead Sciences Price Performance

Gilead Sciences stock opened at $134.06 on Friday. Gilead Sciences, Inc. has a 1 year low of $95.29 and a 1 year high of $157.29. The firm has a 50 day moving average price of $139.59 and a 200 day moving average price of $132.87. The company has a market cap of $166.40 billion, a price-to-earnings ratio of 19.80, a PEG ratio of 1.80 and a beta of 0.31. The company has a debt-to-equity ratio of 0.98, a quick ratio of 1.40 and a current ratio of 1.55.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Thursday, May 7th. The biopharmaceutical company reported $2.03 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.91 by $0.12. Gilead Sciences had a net margin of 28.90% and a return on equity of 49.46%. The firm had revenue of $6.96 billion during the quarter, compared to the consensus estimate of $6.91 billion. During the same period in the previous year, the firm earned $1.81 earnings per share. Gilead Sciences’s revenue was up 4.4% compared to the same quarter last year. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. Sell-side analysts predict that Gilead Sciences, Inc. will post 8.62 earnings per share for the current year.

Gilead Sciences Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Monday, June 29th. Investors of record on Monday, June 15th will be issued a $0.82 dividend. This represents a $3.28 dividend on an annualized basis and a yield of 2.4%. The ex-dividend date is Monday, June 15th. Gilead Sciences’s payout ratio is presently 48.45%.

Insider Activity at Gilead Sciences

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 3,000 shares of the business’s stock in a transaction that occurred on Wednesday, April 15th. The shares were sold at an average price of $140.96, for a total transaction of $422,880.00. Following the completion of the sale, the chief financial officer directly owned 176,191 shares in the company, valued at $24,835,883.36. The trade was a 1.67% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Daniel Patrick O’day sold 10,000 shares of the business’s stock in a transaction that occurred on Tuesday, April 28th. The stock was sold at an average price of $129.16, for a total transaction of $1,291,600.00. Following the sale, the chief executive officer owned 632,567 shares of the company’s stock, valued at approximately $81,702,353.72. This represents a 1.56% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 63,000 shares of company stock worth $9,238,250. 0.30% of the stock is owned by company insiders.

Key Headlines Impacting Gilead Sciences

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Q1 results beat estimates — Gilead reported $2.03 EPS vs. a $1.89 consensus and revenue of $6.96B vs. ~$6.91B, showing underlying quarter strength. Gilead Sciences (GILD) Tops Q1 Earnings and Revenue Estimates
• Positive Sentiment: Management raised its 2026 sales forecast, indicating revenue strength despite other headwinds. Gilead raises 2026 sales forecast, cuts profit outlook due to acquisitions
• Neutral Sentiment: Full?year revenue guidance was issued at roughly $30.0–30.4B, near analyst consensus — so sales expectations are roughly intact even as profit guidance shifted. Gilead Press Release / Slide Deck
• Neutral Sentiment: Shareholders approved the board and executive pay plans at the 2026 meeting — governance items cleared without disruption. Gilead Shareholders Back Board, Pay Plans at 2026 Meeting
• Negative Sentiment: Company withdrew prior profit guidance and now expects an adjusted FY2026 loss of $1.05 to $0.65 per share (versus prior ~$8.45–8.85 outlook and analyst expectations near $8.65), a dramatic revision that hits valuation and investor confidence. Gilead Sciences Expects Loss This Year on Acquired R&D Expenses
• Negative Sentiment: Management attributes the profit swing to acquisition?related charges and financing costs tied to recent deals — these one?time and financing items meaningfully depress reported earnings for the year. Gilead raises 2026 sales forecast, cuts profit outlook due to acquisitions

Analysts Set New Price Targets

A number of brokerages have recently commented on GILD. Daiwa Securities Group lifted their price target on shares of Gilead Sciences from $129.00 to $161.00 and gave the stock an “outperform” rating in a report on Wednesday, February 25th. Weiss Ratings reiterated a “buy (b)” rating on shares of Gilead Sciences in a report on Thursday, January 22nd. Wall Street Zen upgraded shares of Gilead Sciences from a “buy” rating to a “strong-buy” rating in a report on Saturday, March 14th. Royal Bank Of Canada lifted their price target on shares of Gilead Sciences from $118.00 to $123.00 and gave the stock a “sector perform” rating in a report on Tuesday, April 7th. Finally, Sanford C. Bernstein reiterated an “outperform” rating and set a $160.00 price target on shares of Gilead Sciences in a report on Wednesday, February 11th. Twenty-four analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $157.35.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.